CytomX is revolutionizing the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics. CytomX's proprietary Probody™ Platform offers a highly differentiated approach to developing antibody therapeutics.
Probodies are masked antibodies that remain inert in healthy tissue but are activated in the disease microenvironment. This new level of tissue activation and selectivity enables CytomX to access new targets and expand the therapeutic index of existing targets.
CytomX is building a diversified pipeline of Probodies that address a broad range of therapeutic targets in oncology, inflammation and other areas of high unmet medical need.
Read MoreRecent News
6.12.13
CytomX to present at Empowered Antibodies Congress 2013
5.7.13
CytomX Therapeutics Named a Finalist for the 2013 Red Herring Top 100 North America Award
5.3.13
CytomX Presented at PEGS
4.3.13
New Data Highlighting CytomX's Probody Platform and EGFR Probody Drug Conjugate Presented at the AACR Annual Meeting 2013